Skip to main
CLGN
CLGN logo

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies is poised for growth due to strategic corporate initiatives aimed at enhancing its rhCollagen supply and accelerating North American operations through key appointments. The company's advancements in regenerative breast implants position it competitively for first-to-market opportunities within a lucrative addressable market, further solidifying its potential for revenue growth. Additionally, the new distribution agreement in Poland for the Vergenix STR product enhances its market presence across Europe, expanding its revenue-generating capabilities in multiple regions.

Bears say

CollPlant Biotechnologies Ltd shows concerning financial metrics, particularly in its revenue generation across its key markets, which include the United States, Canada, Europe, and Israel. The company's reliance on business collaborators and sales from a niche product line, such as its BioInk for 3D bioprinting, raises uncertainty regarding sustained revenue growth amidst a competitive landscape. Additionally, fluctuating demand in the medical aesthetics market and emerging challenges in product commercialization could hinder the company's ability to achieve consistent profitability.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.